Excitement about the effectiveness and availability of blood biomarker testing for Alzheimer’s disease (AD) has created confusion around whether there’s still a need for other important tools, like cognitive screening. The answer is simple. Cognitive screening is integral to monitoring brain function and identifying impairment in older adults. (But even cognitive screening makers like Neurotrack […]
Read more
The Centers for Medicare and Medicaid Services (CMS) have taken significant steps to improve cognitive care for Medicare beneficiaries. In fact, detecting cognitive impairment is a required element of annual wellness visits (AWV). However, many healthcare providers struggle to implement effective and efficient cognitive screening strategies, resulting in missed opportunities for early detection and care. […]
Read more
The challenge to diagnose and treat cognitive decline in our growing aging population is great. Alzheimer’s diagnosis in the US is predicted to soar (to 13.8 million in 2060, up from 6.2 million in 2021)—and so are nationwide shortages of specialists, including geriatricians and neurologists. This one-two punch puts pressure on primary care physicians (PCPs), […]
Read more
With almost 50 million people worldwide affected by dementia—and Alzheimer’s disease the likely cause in 60% to 80% of these cases—detection and care is at a critical juncture. Despite high prevalence of cognitive disease, significant barriers, healthcare provider burnout, and systemic bottlenecks all interfere with their identification and treatment. By exploring common problems in cognitive […]
Read more
Through technological innovation, policy reform, and greater patient demand, PCPs are now in a position to integrate a quick cognitive screening into their practice offerings.
Read more